Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

BACKGROUND: Pancreatic cancer (PC) is the fourth most common cause of cancer death. Combination therapies with classical chemotherapeutic agents improved treatment of advanced PC at the cost of a relevant toxicity, but the 5-year survival rate remains below 5%. Consequently, new therapeutic options...

Descripción completa

Detalles Bibliográficos
Autores principales: Veschi, Serena, De Lellis, Laura, Florio, Rosalba, Lanuti, Paola, Massucci, Alberto, Tinari, Nicola, De Tursi, Michele, di Sebastiano, Pierluigi, Marchisio, Marco, Natoli, Clara, Cama, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151049/
https://www.ncbi.nlm.nih.gov/pubmed/30241558
http://dx.doi.org/10.1186/s13046-018-0904-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151049/
https://www.ncbi.nlm.nih.gov/pubmed/30241558
http://dx.doi.org/10.1186/s13046-018-0904-2

Ejemplares similares